(R)-3,4-dihydro-2H-1-benzopyran-2-methanol methanesulfonate (ester) | 227297-74-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (R)-3,4-dihydro-2H-1-benzopyran-2-methanol methanesulfonate (ester)
• 英文别名: (R)-3,4-dihydro-2H-1-benzopyran-2-methanol methanesulfonate；(R)-2-Methanesulfonyloxymethylchroman；[(2R)-3,4-dihydro-2H-chromen-2-yl]methyl methanesulfonate
• CAS: 227297-74-7
• 化学式: C₁₁H₁₄O₄S
• 分子量: 242.296
• InChiKey: XDUIVMFFCGNJGD-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-3,4-dihydro-2H-1-benzopyran-2-methanol methanesulfonate (ester) 、 1-(3-aminopropyl)-tetrahydro-2(1H)pyrimidinone 以 四氢呋喃 、 乙醇 为溶剂， 以2.2 g (50.8%)的产率得到(R)-1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-tetrahydro-2(1H)-pyrimidinone ethanedioate
  参考文献：
  名称：

  (Benzodioxan, benzofuran or benzopyran) derivatives having fundic

  摘要：

  本发明涉及化合物的公式(I)，其立体化学异构体形式，N-氧化物形式或药物可接受的酸加成盐形式，其中Alk.sup.1是C.sub.1-6烷二基可选地被羟基，C.sub.1-4烷氧基或C.sub.1-4烷基羧酸基取代; --Z.sup.1 --Z.sup.2 --是一个二价基团; R.sup.1，R.sup.2和R.sup.3各自独立地选择自氢，C.sub.1-6烷基，羟基，卤素等; 或者当R.sup.1和R.sup.2在相邻的碳原子上时，R.sup.1和R.sup.2可以组成一个二价基团; R.sup.4是氢或C.sub.1-6烷基; A是公式--NR.sup.6--Alk.sup.2--(b-1)或--Npiperidinyl--(CH.sub.2).sub.m (b-2)的二价基团，其中m为0或1; R.sup.5是公式##STR1##的基团，其中n为1或2; p.sup.1为0，p.sup.2为1或2; 或者p.sup.1为1或2，p.sup.2为0; X是氧，硫或.dbd.NR.sup.9; Y是氧或硫; R.sup.7是氢，C.sub.1-6烷基，C.sub.3-6环烷基，苯基或苯甲基; R.sup.8是C.sub.1-6烷基，C.sub.3-6环烷基，苯基或苯甲基; R.sup.9是氰基，C.sub.1-6烷基，C.sub.3-6环烷基，C.sub.1-6烷氧羰基或氨基羰基; R.sup.10是氢或C.sub.1-6烷基; Q是一个二价基团。公开了制备所述产品的过程，包含所述产品的制剂以及其作为药物的用途，特别是用于治疗与胃底松弛受损相关的疾病。

  公开号：

  US06133277A1
• 作为产物：
  描述：

  甲基磺酰氯 、 (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanol 在 三乙胺 作用下， 以 四氢呋喃 、 2-羟甲基苯并二氢吡喃 为溶剂， 以95%的产率得到(R)-3,4-dihydro-2H-1-benzopyran-2-methanol methanesulfonate (ester)
  参考文献：
  名称：

  EP1445324

  摘要：

  公开号：

文献信息

• [EN] (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES HAVING FUNDIC RELAXATION PROPERTIES<br/>[FR] DERIVES (DE BENZODIOXANE, DE BENZOFURANE OU DE BENZOPYRANE) POSSEDANT DES PROPRIETES DE RELACHEMENT FUNDIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO1999029687A1

  公开（公告）日：1999-06-17

  The present invention of compounds of formula (I), a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk1 is C¿1-6?alkanediyl optionally substituted with hydroxy, C1-4alkyloxy or C1-4alkylcarbonyloxy; -Z?1-Z2¿- is a bivalent radical; R?1, R2 and R3¿ are each independently selected from hydrogen, C¿1-6?alkyl, hydroxy, halo and the like; or when R?1 and R2¿ are on adjacent carbon atoms, R?1 and R2¿ taken together may form a bivalent radical; R4 is hydrogen or C¿1-6?alkyl; A is a bivalent radical of formula -NR?6-Alk2¿-(b-1), or -Npiperidinyl-(CH¿2?)m(b-2) wherein m is 0 or 1; R?5¿ is a radical of formula (A), wherein n is 1 or 2; p1 is 0, and p2 is 1 or 2; or p1 is 1 or 2, and p2 is 0; X is oxygen, sulfur or =NR9; Y is oxygen or sulfur; R7 is hydrogen, C¿1-6?alkyl, C3-6cycloalkyl, phenyl or phenylmethyl; R?8¿ is C¿1-6?alkyl, C3-6cycloalkyl phenyl or phenylmethyl; R?9¿ is cyano, C¿1-6?alkyl, C3-6cycloalkyl, C1-6alkyloxycarbonyl or aminocarbonyl; R?10¿ is hydrogen or C¿1-6?alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及化合物的公式（I），其立体化学异构体形式，其N-氧化物形式或其药学上可接受的酸加成盐，其中Alk1是C1-6烷基二亚基，可选地取代羟基，C1-4烷氧基或C1-4烷基羰氧基; -Z1-Z2-是双价基团; R1，R2和R3分别独立地选自氢，C1-6烷基，羟基，卤素等; 或当R1和R2在相邻的碳原子上时，R1和R2结合在一起可以形成一个双价基团; R4是氢或C1-6烷基; A是公式-NR6-Alk2-(b-1)或-N哌啶基-(CH2)m(b-2)的双价基团，其中m为0或1; R5是公式（A）的基团，其中n为1或2; p1为0，p2为1或2; 或p1为1或2，p2为0; X是氧，硫或= NR9; Y是氧或硫; R7是氢，C1-6烷基，C3-6环烷基，苯基或苯甲基; R8是C1-6烷基，C3-6环烷基，苯基或苯甲基; R9是氰基，C1-6烷基，C3-6环烷基，C1-6烷氧羰基或氨基羰基; R10是氢或C1-6烷基; Q是双价基团。本发明还公开了制备所述产品的方法，包含所述产品的制剂以及它们作为药物的用途，特别是用于治疗与胃底松弛障碍有关的疾病。
• Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives
  申请人：De Bruyn Frans Leopold Marcel

  公开号：US20050159406A1

  公开（公告）日：2005-07-21

  The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -Z 1 -Z 2 - is a bivalent radical; R 1 , R 2 and R 3 are each independently selected from hydrogen, C 1-6 alkyl, hydroxy, halo and the like; or when R 1 and R 2 are on adjacent carbon atoms, R 1 and R 2 taken together may form a bivalent radical of formula; Alk is optionally substituted C 1-6 alkanediyl; the bivalent radical is a substituted piperidinyl, an optionally substituted pyrrolidinyl, homopiperidinyl, piperazinyl or tropyl; R 5 is a radical of formula wherein n is 1 or 2; p 1 is 0, and p 2 is 1 or 2; or p 1 is 1 or 2, and p 2 is 0; X is oxygen, sulfur or ═NR 9 ; Y is oxygen or sulfur; R 7 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenylmethyl; R 8 is C 1-6 alkyl, C 3-6 cycloalkyl phenyl or phenylmethyl; R 9 is cyano, C 1-6 alkyl, C 3-6 cyclo-alkyl, C 1-6 alkyloxycarbonyl or aminocarbonyl; R 10 is hydrogen or C 1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及式（I）的化合物，其立体化学异构体，其N-氧化物形式或其药学上可接受的酸加成盐，其中-Z1-Z2-是双价基团；R1，R2和R3分别选自氢，C1-6烷基，羟基，卤素等；或当R1和R2位于相邻的碳原子上时，R1和R2可以共同形成式的双价基团；Alk是可选的取代C1-6烷二基基团；双价基团是取代的哌啶基，可选的取代吡咯烷基，同型哌啶基，哌嗪基或茄芷基；R5是式中的基团，其中n为1或2；p1为0，p2为1或2；或p1为1或2，p2为0；X为氧，硫或═NR9；Y为氧或硫；R7为氢，C1-6烷基，C3-6环烷基，苯基或苯甲基；R8为C1-6烷基，C3-6环烷基，苯基或苯甲基；R9为氰基，C1-6烷基，C3-6环烷基，C1-6烷氧羰基或氨基羰基；R10为氢或C1-6烷基；Q为双价基团。公开了制备该产品的过程，包括该产品的配方以及它们作为药物的用途，特别是用于治疗与胃底松弛受损有关的疾病。
• (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
  申请人：——

  公开号：US20030083365A1

  公开（公告）日：2003-05-01

  The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk 1 is C 1-6 alkanediyl optionally substituted with hydroxy, C 1-4 alkyloxy or C 1-4 alkylcarbonyloxy; -Z 1 -Z 2 - is a bivalent radical; R 1 , R 2 and R 3 are each independently selected from hydrogen, C 1-6 alkyl, hydroxy, halo and the like; or when R 1 and R 2 are on adjacent carbon atoms, R 1 and R 2 taken together may form a bivalent radical; R 4 is hydrogen or C 1-6 alkyl; A is a bivalent radical of formula —NR 6 —Alk 2 - (b- 1 ), or —Npiperidinyl-(CH 2 ) m (b- 2 ) wherein m is 0 or 1; R 5 is a radical of formula 2 wherein n is 1 or 2; p 1 is 0, and p 2 is 1 or 2; or p 1 is 1 or 2, and p 2 is 0; X is oxygen, sulfur or ═NR 9 ; Y is oxygen or sulfur; R 7 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenylmethyl; R 8 is C 1-6 alkyl, C 3-6 cycloalkyl phenyl or phenylmethyl; R 9 is cyano, C 1-6 alkyl, C 3-6 cyclo-alkyl, C 1-6 alkyloxycarbonyl or aminocarbonyl; R 10 is hydrogen or C 1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及以下化合物的配方(I)1a立体化学异构体形式、其N-氧化物形式或其药学上可接受的酸加成盐，其中Alk1是C1-6烷基二亚甲基，可选地被羟基、C1-4烷氧基或C1-4烷基羧酸酯取代；-Z1-Z2-是双价基团；R1、R2和R3各自独立地选自氢、C1-6烷基、羟基、卤素等；或当R1和R2在相邻的碳原子上时，R1和R2可以一起形成一个双价基团；R4是氢或C1-6烷基；A是式—NR6—Alk2-(b-1)或—N哌啶基-(CH2)m(b-2)的双价基团，其中m为0或1；R5是式2的基团，其中n为1或2；p1为0，p2为1或2；或p1为1或2，p2为0；X是氧、硫或═NR9；Y是氧或硫；R7是氢、C1-6烷基、C3-6环烷基、苯基或苯基甲基；R8是C1-6烷基、C3-6环烷基、苯基或苯基甲基；R9是氰基、C1-6烷基、C3-6环烷基、C1-6烷氧羰基或氨基羰基；R10是氢或C1-6烷基；Q是双价基团。本发明还公开了制备所述产品的方法、包含所述产品的配方以及它们作为药物的用途，特别是用于治疗与胃底松弛障碍有关的疾病。
• Process for producing optically active chroman derivative and intermediate
  申请人：Mitsuda Masaru

  公开号：US20050014818A1

  公开（公告）日：2005-01-20

  A process for easily producing various optically active chroman derivatives that are useful as pharmaceutical intermediates from inexpensive starting materials is provided. Cyclic hemiacetal (1) obtained from dihydrocoumarin through one step is asymmetrically reduced to produce an optically active halohydrin derivative (3), and the optically active halohydrin derivative (3) is cyclized to produce an optically active chroman derivative (13):

  提供一种从廉价起始材料中轻松制备各种光学活性的色基衍生物作为药物中间体的方法。通过一步反应从二氢香豆素得到的环糖半缩醛（1）经不对称还原制备出光学活性卤代醇衍生物（3），然后将光学活性卤代醇衍生物（3）环化得到光学活性色基衍生物（13）。
• PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN DERIVATIVE AND INTERMEDIATE
  申请人：KANEKA CORPORATION

  公开号：EP1445324A1

  公开（公告）日：2004-08-11

  A process for easily producing various optically active chroman derivatives that are useful as pharmaceutical intermediates from inexpensive starting materials is provided. Cyclic hemiacetal (1) obtained from dihydrocoumarin through one step is asymmetrically reduced to produce an optically active halohydrin derivative (3), and the optically active halohydrin derivative (3) is cyclized to produce an optically active chroman derivative (13):

  本发明提供了一种利用廉价起始原料轻松生产各种光学活性色满衍生物的工艺，这些衍生物可用作药物中间体。 通过一个步骤从二氢香豆素得到的环状半缩醛（1）经不对称还原生成光学活性卤代醇衍生物（3），光学活性卤代醇衍生物（3）经环化生成光学活性色满衍生物（13）：